Cigna Corporation (NYSE: CI) took investors on a wild ride in 2019. The stock plunged more than 20%, only to make a big comeback toward the end of the year. Cigna ultimately delivered a gain of nearly 8% and entered 2020 with strong momentum.
That momentum was put to the test when the global health service company announced its 2019 fourth-quarter and full-year results before the market opened on Thursday. But it looks as if Cigna passed that test. Here are the highlights from the company's Q4 update.
Image source: Getty Images.
By the numbers
Cigna announced Q4 revenue of $38.2 billion, a huge 167% increase from the $14.3 billion reported in the same quarter of the previous year. This result easily beat the average analysts' revenue estimate of $35.1 billion.
The company reported net income in the fourth quarter of $977 million, or $2.60 per share, based on generally accepted accounting principles (GAAP). This reflected significant improvement from Cigna's net income of $144 million, or $0.55 per share, generated in the prior-year period.
Cigna's adjusted non-GAAP bottom line also looked good in the fourth quarter. The company announced Q4 adjusted earnings per share of $4.31, up 75% year over year. The consensus Wall Street estimate was for Cigna to post adjusted EPS of $4.20.
Behind the numbers
There was a simple explanation behind Cigna's tremendous year-over-year growth. The company acquired pharmacy benefits manager Express Scripts on Dec. 20, 2018.
Express Scripts is now part of Cigna's health services segment. This segment generated adjusted revenue of $25.6 billion in Q4. Health services made $3.3 billion in revenue in the prior-year period.
Cigna's integrated medical segment includes the company's U.S. commercial and government insurance products. The integrated medical segment delivered adjusted revenue of $9.2 billion in the fourth quarter, up 11% year over year. This growth stemmed primarily from adding new commercial customers and premium increases.
The company's international markets segment sells supplemental health, life, and accident insurance in countries outside the U.S. and provides healthcare benefits for employees of multinational organizations and individuals who travel extensively to other countries. Cigna reported that the international markets segment had adjusted revenue of $1.43 billion in Q4, an increase of 5.5% year over year.
Cigna also sells group long-term and short-term disability products along with group life, accident, voluntary, and specialty insurance products in its group disability and other operations segment. Adjusted revenue for this segment in the fourth quarter rose nearly 4% year over year to $1.29 billion.
The company projects adjusted revenues of between $154 billion and $156 billion for full-year 2020. Cigna expects that adjusted income from operations for 2020 will be between $6.8 billion and $7 billion. On a per-share basis, adjusted earnings for full-year 2020 are expected to be between $18.00 and $18.60.
Cigna CEO David Cordani said, "Our strong momentum going into 2020 positions us for continued growth, and to deliver sustained value for our customers and clients, as we create greater affordability, predictability and simplicity for their benefit."
There are some factors that could slow Cigna's momentum down this year. The U.S. presidential campaign negatively affected some healthcare stocks in 2016 and could do so again in 2020. A nasty flu season and the potential for a wider outbreak of the coronavirus could also drive medical costs higher, eating into Cigna's profits.
10 stocks we like better than Cigna Corp.
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Cigna Corp. wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of December 1, 2019
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.